SILVERARC CAPITAL MANAGEMENT, LLC

Position in XENE — Xenon Pharmaceuticals Inc.

CIK 1816307 BOSTON, MA

Position in XENE

as of Jun 30, 2026 · filed Aug 13, 2026 Compact

Position Value

$11,276,515

-$223,170 QoQ

Shares Held

186,821

-5.5% QoQ

Ownership

0.193%

of shares outstanding

% of Portfolio

1.26%

of 13F equity value

Holder Rank

#86

of 314 holders

Holding Since

Sep 2021

14 quarters on record

Voting authority Sole 100% Shared 0% None 0%

Healthcare · as of Jun 30, 2026

SILVERARC CAPITAL MANAGEMENT, LLC holds $802,586,993 across 53 Biotechnology names. XENE ranks #24 (1.4% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	ASND	Ascendis Pharma A/S	206,234	$55,006,732
2	CELC	Celcuity Inc.	500,996	$52,414,201
3	COGT	Cogent Biosciences, Inc.	1,280,707	$49,563,360
4	URGN	UroGen Pharma Ltd.	1,301,979	$47,912,827
5	IMNM	Immunome Inc.	2,017,009	$42,740,420
6	DNTH	Dianthus Therapeutics, Inc. /DE/	390,000	$38,017,200
7	RYTM	Rhythm Pharmaceuticals, Inc.	311,461	$34,581,514
8	ORKA	Oruka Therapeutics, Inc.	352,802	$33,576,166

14 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-06-30	$11,276,515	186,821	-5.5%	Shares	Sole	2026-08-13
2026-03-31	$11,499,685	197,759	+1853.9%	Shares	Sole	2026-05-14
2025-03-31	$339,559	10,121	-84.7%	Shares	Sole	2025-05-14
2024-03-31	$2,845,174	66,090	-59.5%	Shares	Sole	2024-05-15
2023-12-31	$7,515,518	163,168	+202.2%	Shares	Sole	2024-02-14
2023-09-30	$1,844,503	53,996	-45.9%	Shares	Sole	2023-11-13
2023-06-30	$3,840,606	99,756	+3.2%	Shares	Sole	2023-08-14
2023-03-31	$3,458,852	96,643	-61.9%	Shares	Sole	2023-05-15
2022-12-31	$10,001,616	253,655	+3.1%	Shares	Sole	2023-02-14
2022-09-30	$8,880,311	245,992	+5.7%	Shares	Sole	2022-10-28
2022-06-30	$7,076,604	232,630	+130.1%	Shares	Sole	2022-07-25
2022-03-31	$3,090,046	101,081	+1.1%	Shares	Sole	2022-05-13
2021-12-31	$3,124,000	100,000	+414.6%	Shares	Sole	2022-02-14
2021-09-30	$296,920	19,432	—	Shares	Sole	2021-11-15
No filing history on record for this holder in this stock.